News
New Molecular Target For Cancer Therapy Found Through Study
The Ohio State University Comprehensive Cancer Center, Richard J. Solove Research Institute, and James Cancer Hospital have discovered a new molecular therapeutic target that could...
Research Insight
New study demonstrates advantages of PentaHibe for cryopreservation of T cells
New data published by Haastrup EK. et. al in Transfusion and Apheresis Science1 demonstrates the efficacy of PentaHibe® in cryopreservation of T cells.
PentaHibe® (pentaisomaltose), a...
Clinical Trials
Mixed Oxford/Pfizer vaccine schedules generate robust immune response against COVID-19, finds Oxford-led study
Alternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.
In a...
Research Insight
A ‘Single Dose’ of vaccine sufficient for those already infected with COVID-19, says AIG Study
During the second COVID wave when cases were growing exponentially; unfortunately, the vaccination rate took a downturn. As of 27th April, when the growth rate...
Press Releases
Aevi Genomic Medicine Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody
Aevi Genomic Medicine, Inc. announced that it has obtained the right to exercise an exclusive global license for MEDI2338, a Phase 2-ready fully human monoclonal...
Articles
Navigating Russia’s Compliance Regulations; Arguably the Most Complex in the World
Russia’s increasing reliance on pharmaceutical-driven healthcare is resulting in a growing consumer demand for drugs of all types.
Over the past few decades, the country’s domestic...
Research Insight
Lonza and AllCells Join Forces for Global Commercialization of Hematopoietic Primary Cells
Lonza and AllCells have entered into a private label partnership for the manufacture and global commercialization of an extensive range of hematopoietic primary cells. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.